Trial Profile

An investigator-initiated trials phase Ib/II trial of CT-0596 for R/R multiple myeloma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CT 0596 (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

12 Jan 2026 New trial record
28 Dec 2025 According to a CARsgen media release, company has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy product, CT0596, for treatment of relapsed/refractory multiple myeloma.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com